Skip to main content

Table 2 Means and standard deviations of SNV predicted neoantigens, mutations/Mb of non-silent mutations and TIL fractions in the indicated tumor populations

From: RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer

  SNVneoantigens (predicted)a NonsilentMUTS (muts/Mb)b TILs fraction (%)c
DWT 84.7 ± 86.3 5.0 ± 5.3 6.0 ± 6.4
RB1 only 141.6 ± 145.1 8.2 ± 7.8 7.8 ± 6.6
TP53 only 102.7 ± 81.4 6.4 ± 4.7 7.6 ± 6.3
RB1&TP53 135.6 ± 101.4 8.4 ± 6.2 9.1 ± 7.8
Kruskal-Wallis (p value) a < 0.001 b < 0.001 c 0.002
RB1 WT 91.2 ± 84.8 5.5 ± 5.1 6.6 ± 6.4
RB1 MUT 117.1 ± 85.4 7.3 ± 5.2 8.6 ± 8.2
RB1 HD 180.3 ± 158.5 10.5 ± 8.8 8.7 ± 5.6
Kruskal-Wallis (p value) a < 0.001 b < 0.001 c 0.015
TP53 WT 93.5 ± 99.3 5.5 ± 5.9 6.3 ± 6.4
TP53 TRUNCATED 106.6 ± 90.0 7.1 ± 5.9 9.1 ± 8.3
TP53 MISSENSE 123.7 ± 91.9 7.5 ± 5.1 7.8 ± 6.1
Kruskal-Wallis (p value) a < 0.001 b < 0.001 c 0.002